Author

admin

Browsing

As the robotics industry prepares for significant technological advances in artificial intelligence (AI), it’s no surprise that the top robotics stocks are gaining attention.

Chief executive officer of Hangzhou Unitree Technology, Wang Xingxing, told the World Robots Conference in Beijing in August 2025 that the industry could be about one to three years away from a breakthrough comparable to the ChatGPT moment. He also expressed optimism about the future, predicting that at least one company might develop a general-purpose robotic AI model by the end of 2025.

While these transformative AI advancements promise to reshape robotics broadly, current market data shows that the automotive industry continues to drive a large share of robotics orders. However, according to data from the Association for Advancing Automation, rapid growth in demand from the food and consumer products and life science sectors was also notable in 2024.

Surgical robots are increasingly being used in a variety of surgery types, such as cardiac and spinal, allowing for better patient outcomes.

With technological breakthroughs just on the horizon and diverse sectors driving demand, now is an opportune moment to explore the top robotics stocks poised to capitalize on this rapidly evolving industry.

10 largest robotics stocks

This list of top robotics stocks by market cap was compiled using TradingView’s stock screener. All market cap and share price information was current as of September 3, 2025.

1. NVIDIA (NASDAQ:NVDA)

Share price: US$170.62
Market cap: US$4.15 trillion

NVIDIA’s robotics business has surged ahead in 2025 with major technology releases and expanding industry partnerships, establishing it as a core infrastructure provider for robotic intelligence. Its Jetson Thor platform offers 7.5 times more compute and 3.5 times greater energy efficiency than its predecessor.

The company is driving physical AI, the fourth wave of the AI revolution, through its Cosmos model, which allows developers to train robots for diverse scenarios, a critical component to advancing autonomous vehicles and humanoid robots.

2. Tesla (NASDAQ:TSLA)

Share price: US$334.09
Market cap: US$1.08 trillion

Tesla’s robotics business is becoming increasingly central to its CEO, Elon Musk, who claims its Optimus humanoid robot will eventually become the company’s core value driver. The company is focused on developing and scaling Optimus, although its goal of producing 5,000 in 2025 is reportedly behind schedule as of July. Tesla is aiming to produce 1 million units annually by 2030.

The long-term goal is to achieve fully autonomous robots that can be deployed across manufacturing, logistics, elder care and residences, which it detailed in its Master Plan IV released in early September.

3. Thermo Fisher Scientific (NYSE:TMO)

Share price: US$484.55
Market cap: US$182.97 billion

Thermo Fisher Scientific is a medical device company that is one of the world’s most respected brands in healthcare, scientific research, safety and education. Its products and services cover a broad range of high-end analytical instruments, chemistry and consumable supplies, automated laboratory robotics and software designed primarily for medical researchers, clinicians and scientists.

In June 2025, Thermo Fisher Scientific partnered with Cellular Origins, which owns the Constellation robotic manufacturing platform, to scale up late-stage trials and commercial production of cell and gene therapies.

Outside the life science sector, the company launched the Vulcan Automated Lab in early 2025, integrating robotic sample handling, AI and advanced electron microscopy to improve semiconductor development.

4. Qualcomm (NASDAQ:QCOM)

Share price: US$157.28
Market cap: US$169.71 billion

Qualcomm’s specialty is designing and manufacturing semiconductors, software and wireless telecommunications products. In recent years, the company has devoted attention to AI-related technologies such as on-device AI, edge cloud AI and technologies that combine 5G and AI. These technologies also underlie Qualcomm’s advancements in the robotics space.

Qualcomm’s Snapdragon platform is a high-performance, low-power system-on-a-chip designed for AI, 5G connectivity and real-time processing used in a variety of sectors, including in robotics.

The Qualcomm Robotics RB6 Platform supports next-generation robotics and intelligent machines. According to the company, some applications include autonomous mobile robots, delivery robots, highly automated manufacturing robots, urban air mobility aircrafts and autonomous defense solutions.

It also has the Flight RB5 5G platform that specifically targets autonomous drones and flying robots, integrating multiple sensors, multiple cameras, 5G and Wi-Fi 6 connectivity to enable advanced navigation and AI-driven control.

5. Boston Scientific (NYSE:BSX)

Share price: US$107.53
Market cap: US$159.33 billion

Boston Scientific is a medical device company leading in cardiac and electrophysiology robotics and advanced ablation systems.

Its OPAL HDx mapping systems allow physicians to precisely navigate within the heart through 3D mapping, position tracking and more. It employs the company’s FARAPULSE Pulsed Field Ablation system, which generated over US$1 billion in revenue in its first year and now holds expanded US Food and Drug Administration (FDA) approval for both pulmonary vein and posterior wall ablation.

Strategic acquisitions since 2024 include Silk Road Medical, Axonics, Bolt Medical and SoniVie, giving the company access to a wealth of product offerings to address patient needs and create new revenue streams.

6. Intuitive Surgical (NASDAQ:ISRG)

Share price: US$441.18
Market cap: US$158.15 billion

A leader in surgical robotics, Intuitive Surgical is the company behind the da Vinci minimally invasive surgical system. The original da Vinci system gained FDA approval in 2000, making it the first completely robotic surgical system to receive clearance from the FDA.

Intuitive Surgical now provides a suite of its da Vinci robotics-assisted surgical systems to doctors and hospitals, and they are used by surgeons across all 50 US states and 72 countries around the world.

New products, including the Ion robot for lung biopsies and the SureForm SP stapler, are experiencing unprecedented growth. Their AI-driven features contribute to reducing error rates and enhancing outcomes.

7. Stryker (NYSE:SYK)

Share price: US$388.56
Market cap: US$148.55 billion

Stryker is another leading medical technology company. It develops medical equipment, instruments and surgical robotics for healthcare systems worldwide. Its surgical robotics systems incorporate health data and AI to improve health outcomes for patients.

Stryker’s Mako 4 robotic arm system for assisted joint replacement surgery can be used in partial knee, total knee, hip and spine surgeries, and a version for shoulder surgeries was recently introduced. The company showcased an upgrade to its Mako Total Hip system during the American Academy of Orthopaedic Surgeons’ 2025 Annual Meeting in San Diego in March.

Stryker launched Ortho Q Guidance, its surgical guidance system for knee and hip procedures, in July 2023. The platform can be integrated into robotics technology.

8. Honeywell International (NASDAQ:HON)

Share price: US$214.00
Market cap: US$135.87 billion

Engineering and technology company Honeywell International develops and manufactures technological solutions for a variety of sectors, including energy, security, safety, productivity and global urbanization. Its four business divisions are: aerospace, building technologies, performance materials and technologies, and safety and productivity solutions.

For more than a quarter century, Honeywell’s smart robotics technologies, including autonomous mobile robots and order-picking AI-powered robots, have provided warehouse automation solutions targeting transport, order picking, palletizing and depalletizing.

In 2025, Honeywell announced a strategic partnership with Teradyne Robotics, a division of Teradyne (NASDAQ:TER), to deliver end-to-end automation solutions using Teradyne’s autonomous mobile robots and collaborative robots and Honeywell’s software.

9. Medtronic (NYSE:MDT)

Share price: US$92.25
Market cap: US$118.33 billion

Medtronic is one of the largest medical device manufacturing companies in the world. The firm’s technologies include cardiac devices, surgical robotics, insulin pumps, surgical tools and patient monitoring systems.

Medtronic’s Hugo robotic-assisted surgery system is a modular platform with four independent robotic arms, designed to improve precision, flexibility and surgeon ergonomics in minimally invasive soft tissue surgeries like urology and gynecology.

It features 3D high-definition visualization, advanced AI-powered analytics and an open console for better surgeon communication. Hugo offers a cost-effective and adaptable alternative to traditional systems and has been commercially used in North America since 2023.

10. Texas Instruments (NASDAQ:TXN)

Share price: US$195.74
Market cap: US$4.78 billion

Texas Instruments is a leading semiconductor manufacturer whose robotics business focuses on supplying high-precision analog chips, sensors, embedded processors and motor control solutions for industrial automation, factory robots, automotive robotics and smart devices.

Texas Instruments partnered with KUKA in April 2025 to jointly advance next-generation industrial robotics. The collaboration focuses on integrating TI’s precision analog sensors and real-time motor control chips into KUKA’s robot arms and automation platforms, resulting in safer, more energy-efficient and adaptive robots for smart factories and logistics.

FAQs for robotics stocks

What is robotics?

In simple terms, robotics is defined as the branch of technology that deals with the design, construction, operation and application of robots. The field has subsets such as automation and AI.

Both automation and robotics have been used interchangeably, but these terms have certain differences. Automation is the process of using technology to carry out specific tasks, and not all robots are designed for automation. That said, most robots are, especially those with industrial uses.

What are the five major fields of robotics?

The five major fields of robotics are: operator interface, mobility, manipulator and effectors, programming and sensing and perception.

Operator interface is better described as human-robot interface — it’s the means by which humans can communicate commands to a robot. This might be in the form of a touchscreen on a control panel.

Mobility refers to the ability of a robot to move in its environment, while manipulators and effectors allow the robot to interact with its environment. Think of an autonomous mobile robot moving around a warehouse to stack inventory on a pallet. For its part, programming involves the language used to communicate commands to the robot.

Meanwhile, sensing and perception allows the robot to acquire information about its environment and perform tasks based on that information. This is important for autonomous vehicle technology.

How can I invest in robotics?

For investors looking to enter the robotics sector, large companies like the ones listed above may be a good place to start. Those with a broader approach who would rather put their money into the sector as a whole rather than in a single company may want to consider exchange-traded funds focused on robotics.

Is Boston Dynamics public?

Boston Dynamics is a private mobile robotics engineering firm that specializes in building robots and software for human simulation. Originally part of the Massachusetts Institute of Technology, Boston Dynamics is held by Hyundai (80 percent) and Softbank Group (TSE:9984) (20 percent).

Can I buy stock in Miso Robotics?

Miso Robotics is a privately held company, which means it is not listed on any stock exchange. The company develops and manufactures AI-driven robots, including automatic fry cook Flippy, that help restaurants with food preparation.

Water, hygiene and infection prevention company Ecolab (NYSE:ECL) has partnered with Miso Robotics “to explore new opportunities to enhance food safety, hygiene, and efficiency in the food industry through automation and digital solutions.”

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Founded in 2009 and listed in 2011, Angkor Resources (TSXV:ANK,OTCQB:ANKOF) has developed a dual focus on energy and minerals across Asia and North America.

Angkor Resources is advancing a dual-track strategy across energy and minerals. In Canada, its subsidiary EnerCam Exploration generates revenue from oil production, water disposal, and gas processing, while also pioneering carbon capture and conversion solutions.

In Cambodia, subsidiary EnerCam Resources is driving the nation’s first-ever onshore oil and gas exploration on Block VIII, positioning the company for transformational growth. On the mineral side, Angkor is a first-mover in Cambodia’s underexplored belts, with licenses at Andong Meas and Andong Bor targeting both precious and base metals, where exploration has already confirmed copper porphyry systems and high-grade gold mineralization.

Angkor mitigates risk by diversifying revenue, combining recurring Canadian cash flow with high-impact exploration in Cambodia, where management prioritizes hydrocarbons and copper, highlighting 25 million recoverable barrels and significant copper-gold potential.

Company Highlights

  • Diversified Energy & Mineral Portfolio: Exposure to high-impact oil and gas exploration in Cambodia (Block VIII), recurring energy revenues in Canada, and copper-gold porphyry systems with gold epithermal near-surface prospects in Cambodia.
  • Near-term Catalysts:
    • Results from copper porphyry in Cambodia within 30 to 60 days;
    • Seismic completion and interpretation for drill targets on Block VIII within 90 days; and
    • Acquisition of oil production for increased recurring revenue streams.
  • Transformational Asset: Block VIII is Cambodia’s first onshore oil and gas exploration license, strategically located near export infrastructure. Potential minimum targets estimated at 25 to 50+ million recoverable barrels.
  • Revenue-backed Model: EnerCam Canada provides recurring revenue streams via oil production, water disposal, gas processing, and carbon capture solutions, insulating Angkor from over-reliance on equity markets.
  • Strong ESG Commitment: Recognized at the United Nations for sustainability, Angkor integrates carbon capture, community partnerships and environmental responsibility into every project.
  • Aligned Shareholder Base: Over 40 percent insider ownership with regular insider buying, demonstrating management’s confidence in long-term growth.

This Angkor Resources profile is part of a paid investor education campaign.*

Click here to connect with Angkor Resources (TSXV:ANK) to receive an Investor Presentation

This post appeared first on investingnews.com

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) (‘Lobe Sciences’ or the ‘Company’) a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming ArcStone-Kingswood Growth Summit in Toronto, taking place at the St. Regis Toronto on September 18, 2025. Dr. Frederick D Sancilio, CEO of lobe sciences ltd. will be presenting the company’s recent milestones and future growth strategy.

The ArcStone-Kingswood Growth Summit will be hosting over 20 companies and a curated group of investors for a full day of pre-arranged, targeted 1-on-1 meetings, panel discussions and networking opportunities.

Alongside the schedule of pre-booked meetings matching investors with appropriate projects, the conference program will provide amble opportunities to mix and mingle with the industry professionals and catch up on key industry developments.

Interested investors who would like to attend the ArcStone-Kingswood Growth Summit can register to request for a free invitation here.

About ArcStone Securities and Investments Corp.

ArcStone Securities and Investments Corp. is a diversified financial services firm with offices in Toronto and New York. Our firm specializes in providing bespoke solutions to mid-market companies worldwide, with a particular focus on cross-border transactions between Canada and the United States. Our partnership with Kingswood US enhances our ability to offer a full spectrum of financial services to our clients.

About Kingswood US

Kingswood US is a mid-market investment bank with a strong retail equity capital markets franchise and deep-rooted investment bank. The firm is dedicated to providing comprehensive financial services, including investment banking, wealth management, and capital raising, to clients across the United States.

About lobe sciences ltd.

Lobe Sciences Ltd. is a clinical stage biopharmaceutical company focused on developing novel therapies for rare neurological and hematological conditions. The company operates through two subsidiaries:

  • Altemia, Inc. is addressing sickle cell disease with two complementary assets: a medical food currently in early-stage distribution, and S-100, a patent-pending therapeutic candidate designed to treat the underlying pathology of the disease.

Lobe’s pipeline is differentiated by intellectual property, clinical momentum, and a strategic focus on high-value, underserved markets.

For additional Information, please contact:

lobe sciences ltd.
info@lobesciences.com
www.lobesciences.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265683

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

Like its sister metal gold, silver has been attracting renewed attention as a safe-haven asset.

Although silver continues to exhibit its hallmark volatility, a silver bull market is well underway in 2025.

Experts are optimistic about the future, and as the silver price’s momentum continues in 2025, investors are looking for price forecasts and asking, “What was the highest price for silver?”

The answer reveals how much potential there is for the silver price to rise.

Read on for a look at silver’s historical moves, its new all-time high price and what they could mean for both the price of silver today and the white metal’s price in the future.

In this article

    How is silver traded?

    Before discovering what the highest silver price was, it’s worth looking at how the precious metal is traded. Knowing the mechanics can be useful in understanding why and how its price changes on a day-to-day basis and beyond.

    Put simply, silver bullion is traded in dollars and cents per ounce, with market activity taking place worldwide at all hours, resulting in a live silver price. Key commodities markets like New York, London and Hong Kong are just a few locations where investors trade the metal. London is seen as the center of physical silver trade, while the COMEX division of the New York Mercantile Exchange, called the NYMEX, is where most paper trading is done.

    There are two popular ways to invest in silver. The first is through purchasing silver bullion products such as bullion bars, bullion coins and silver rounds. Physical silver is sold on the spot market, meaning that to invest in silver this way, buyers pay a specific price for the metal — the silver price per ounce — and then have it delivered immediately.

    The second is accomplished through paper trading, which is done via the silver futures market, with participants entering into futures contracts for the delivery of silver at an agreed-upon price and time. In such contracts, two positions can be taken: a long position to accept delivery of the metal or a short position to provide delivery.

    Paper trading might sound like a strange way to get silver exposure, but it can provide investors with flexibility that they wouldn’t get from buying and selling bullion. The most obvious advantage is perhaps the fact that trading in the paper market means silver investors can benefit long term from holding silver without needing to store it. Furthermore, futures trading can offer more financial leverage in that it requires less capital than trading in the physical market.

    Market participants can also invest in silver through exchange-traded funds (ETFs). Investing in a silver ETF is similar to trading a stock on an exchange, and there are several silver ETFs to choose from. Some ETFs focus on physical silver bullion, while others focus on silver futures contracts. Still others focus on silver stocks or follow the live silver price.

    What is silver’s all-time high price?

    The silver all-time high was US$56.86, which it set on November 28, 2025.

    However, until October 9 of this year, the white metal’s all-time high had been the same for 45 years — silver’s former all-time high was US$49.95, and it was set on January 17, 1980.

    It’s worth unpacking what happened, because price didn’t exactly reach that level by honest means.

    As Britannica explains, two wealthy traders called the Hunt brothers attempted to corner the market by buying not only physical silver, but also silver futures — they took delivery of those silver futures contracts instead of taking legal tender in the form cash settlements. Their exploits ultimately ended in disaster: On March 27, 1980, they missed a margin call and the silver market price plunged to US$10.80. This day is infamously known as Silver Thursday.

    That record silver price wouldn’t be tested again until April 2011, when it reached US$47.94. This was more than triple the 2009 average silver price of US$14.67, with the price uptick coming on the back of very strong investment demand.

    So what happens next? While silver has officially broken its 1980 peak, it is still well below that price point adjusted for inflation. It remains to be seen just how high silver can go.

    Silver’s price history since 2011

    Silver price chart, November 10, 2010, to November 10, 2025.

    Chart via SilverPrice.org.

    After its 2011 peak, silver’s price pulled back over the following years before settling between US$15 and US$20 for much of the second half of last decade. An upward trend in the silver price started in mid-2020, when it was spurred on by the economic uncertainty surrounding the COVID-19 pandemic. The price of silver breached the key US$26 level in early August 2020, and soon after tested US$30. However, it failed to make substantial progress past that.

    In the spring of 2023, the silver price surged by 30 percent, briefly rising above US$26 in early May; however, the precious metal cratered back down to US$20.90 in early October. Later that month, silver advanced toward the US$23 level on the back of safe-haven demand due to the outbreak of the Israel-Hamas war.

    Following remarks from US Federal Reserve Chair Jerome Powell, speculation about interest rate reductions sent the price of silver to US$25.48 on November 30, its highest point for the fourth quarter.

    After starting 2024 on a low note, the white metal saw gains in March on rising Fed rate cut expectations. The resulting upward momentum led silver to reach a Q1 high of US$25.62 on March 20 before breaking through the US$30 mark on May 17. The silver price reached a then 12 year high of US$32.33 on May 20.

    In Q3, the metal’s price slid down below the US$27 mark to as low as US$26.64 by August 7 alongside its industrial cousin copper. Heading into Q4 2024, silver reversed course to the upside, tracking the record breaking moves in the gold price. Silver once again breached the US$30 level on September 13 and continued higher.

    On October 21, the silver price moved as high as US$34.20 during the trading day, up more than 48 percent since the start of the year and its highest level in 12 years. However, silver spent the rest of the year in decline, bottoming out at US$28.94 on December 30.

    Silver’s price performance in 2025

    Silver price chart, December 31, 2024, to November 28, 2025.

    The silver price experienced a momentum shift at the start of 2025, breaking through the US$30 barrier as early as January 5, and reaching US$31.31 by January 29. The metal continued to post gains through much of February and March, climbing to US$32.94 on February 20 and then peaking at its quarterly high of US$34.21 on March 28.

    Following US President Donald Trump’s tariff announcements on April 2, silver slumped to below US$30. While the Trump administration’s tariff policies have been largely beneficial for safe-haven assets like precious metals, there were concerns that the threat of tariffs could weaken industrial demand, which could cool price gains in the silver market.

    Yet those concerns were pushed to the back burner as recent economic and geopolitical events have raised analysts’ expectations of a September rate cut by the Fed. The benchmark rate has not changed since November 2024.

    On June 5, the silver price rose to a 13 year high of US$36.05 in early morning trading, before retreating toward the US$35.50 mark. By June 16, the white metal had broken through the US$37 mark for the first time since May 2011.

    In July, increasing geopolitical strife in the Middle East and Russia-Ukraine coupled with a positive outlook for China’s solar power industry proved price positive for both silver’s precious metals and industrial angles.

    The silver price overtook the US$39 level to reach US$39.24 on July 22.

    These same forces, coupled with the nearly unanimous rate cut expectations, launched the price of silver to over US$40 on August 31 for the first time since 2011, and by September 3 it had climbed as high as US$41.45. Silver continued climbing through September, progressively breaking level after level to top US$47 by the month’s end.

    Silver started Q4 by continuing its ascent, breaking through its 2011 peak and topping US$48 on October 3.

    The silver price officially surpassed its all-time US dollar high of US$49.95 — set in 1980 on October 9 — as it climbed to US$51.14 during trading that day. The white metal had already beaten its all-time highs in most currencies, including Canadian dollars and Australian dollars, on September 22.

    It continued climbing even higher on the safe-haven demand fundamentals behind its 2025 momentum. Helping drive that demand in October was escalating trade tensions between the US and China, leading to export controls on additional rare earth metals by China and threats of 100 percent tariffs on Chinese imports by the US.

    While silver pulled back to around US$48 in late October, news that the US government shut down had come to an end on November 9 drove the silver price back above US$50.

    Silver’s foray above the US$56 level on November 28 came on the back of an outage at the Comex, where trading was briefly halted due to a ‘cooling issue’ at a CyrusOne data center used by the exchange.

    Silver supply and demand dynamics

    Market watchers are curious as to whether the silver price will continue its upward trajectory in 2025. Only time will tell, and it will depend on the white metal’s ability to remain above the critical US$30 level.

    Like other metals, the silver spot price is most heavily influenced by supply and demand dynamics. However, as the information above illustrates, the silver price can be highly volatile. That’s partially due to the fact that the metal is subject to both investment and industrial metal demand within global markets.

    In other words, it’s bought by investors who want it as a store of wealth, as well as by manufacturers looking to use it for different applications that are incredibly varied. For example, silver has diverse technological applications and is used in devices like batteries and catalysts, but it’s also used in medicine and in the automotive industry.

    In terms of supply, the world’s three top producers of the metal are Mexico, China and Peru. Even in those countries silver is usually a by-product — for instance, a mine producing primarily gold or lead might also have silver output.

    The Silver Institute’s latest World Silver Survey, put together by Metals Focus, outlines a 0.9 percent increase in global mine production to 819.7 million ounces in 2024. This was in partly the result of a return to operations at Newmont’s (TSX:NGT,NYSE:NEM,ASX:NEM) Peñasquito mine in Mexico following a suspension of activity brought about by strike action among workers and improved recoveries out of Fresnillo (LSE:FRES,OTC Pink:FNLPF) and MAG Silver’s (TSX:MAG,NYSEAMERICAN:MAG) Juanicipio. Silver output also increased in Australia, Bolivia and the US.

    The firm is forecasting a 1.9 percent rise in global silver mine production to 823 million ounces in 2025. Much of that growth is expected to come out of Mexico, and it is also projecting output will rise in Chile and Russia.

    Lower production from Australia and Peru will offset some of these gains.

    Looking at demand, Metals Focus sees growth in 2025 flatlining as industrial fabrication takes a hit from the global tariff war. This could be tempered by an anticipated rebound in demand from physical investment in silver bars and coins.

    The silver market is expected to experience a substantial deficit of 117.6 million ounces in 2025, amounting to the sixth straight year of supply shortage for the metal.

    Is the silver price manipulated?

    As a final note on silver, it’s important for investors to be aware that manipulation of prices is a major issue in the space.

    For instance, in 2015, 10 banks were hit in a US probe on precious metals manipulation. Evidence provided by Deutsche Bank (NYSE:DB) showed “smoking gun” proof that UBS Group (NYSE:UBS), HSBC Holdings (NYSE:HSBC), the The Bank of Nova Scotia (TSX:BNS) and other firms were involved in rigging silver rates from 2007 to 2013. In May 2023, a silver manipulation lawsuit filed in 2014 against HSBC and the Bank of Nova Scotia was dismissed by a US court.

    JPMorgan Chase & Co. (NYSE:JPM) has been long at the center of silver manipulation claims as well. For years the firm has been in and out of court for the accusations. In 2020, JPMorgan agreed to pay US$920 million to resolve federal agency probes regarding the manipulation of multiple markets, including precious metals.

    In 2014, the London Silver Market Fixing stopped administering the London silver fix, which had been used for over a century to fix the price of silver. It was replaced by the LBMA Silver Price, which is run by ICE Benchmark Administration, in a bid to increase market transparency.

    Market watchers like Ed Steer have said that the days of silver manipulation are numbered, and that the market will see a significant shift when the time finally comes.

    Investor takeaway

    Silver has neared US$50 multiple times, including its all-time high, and as momentum continues for the silver price in 2025 investors are wondering if it could reach those heights once again.

    While it’s impossible to know for sure what’s next for silver, keeping an eye on the factors driving its performance, including gold’s performance, geopolitics, the economy and industrial demand, will help investors make decisions on when to buy and sell.

    Securities Disclosure: I, Melissa Pistilli, currently hold no direct investment interest in any company mentioned in this article.

    This post appeared first on investingnews.com

    French nuclear group Orano said that it “strongly condemns” the removal of uranium from the SOMAÏR mine in northern Niger.

    The company called the transfer illegal and a direct breach of the International Centre for Settlement of Investment Disputes’ (ICSID) September ruling, which prohibits the material from being sold or moved without the company’s consent.

    Orano said it learned of the shipment only after media reports disclosed that uranium had been taken from the Arlit-based facility, which has been under the control of Niger’s military government since late 2024.

    The company went on to explain “ (it) is not the initiator of this shipment,” adding that it has no official information on the quantity removed, the shipment’s destination, or the conditions of its transport.

    The incident deepens an already severe standoff that has been building for more than a year, following the military junta’s decision in December 2024 to block Orano from operating the mine despite the company’s majority stake.

    At the time, Orano publicly confirmed it had lost operational control, noting that board-approved directives were no longer being carried out and that authorities were preventing the suspension of production expenses.

    The situation escalated further in June 2025, when Niger announced it would nationalize SOMAÏR outright.

    The government accused Orano—a firm it described as “owned by the French state—a state openly hostile toward Niger since July 26, 2023” — of “irresponsible, illegal, and unfair behaviour.”

    Authorities said the mining agreement had expired in December 2023 and argued that nationalization was an assertion of “full sovereignty.” Orano, which held a 63 percent stake in the venture, declined to comment at the time but continued to pursue arbitration and legal action.

    The dispute produced a ruling favorable to Orano in September. The ICSID tribunal ordered Niger “not to sell, transfer, or even facilitate the transfer to third parties of uranium produced by SOMAÏR” that was being held in violation of Orano’s rights.

    That decision has now become central to the new controversy, with the latest shipment appearing to defy the tribunal’s directive.

    Orano said the uranium transfer constitutes a “breach” of the ruling and warned it is prepared to take further steps in response. The company said it reserves the right to take any additional action necessary, including criminal proceedings against third parties, should the material be taken in violation of its offtake entitlement.

    Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

    This post appeared first on investingnews.com

    Recently, Rebecca Taibleson appeared before the Senate Judiciary Committee for her confirmation hearing to a Wisconsin-based seat on the United States Court of Appeals for the Seventh Circuit, a key step toward further solidifying President Trump’s strong judicial legacy. In choosing Taibleson, Trump selected a standout from a highly qualified field. She’s not only a seasoned prosecutor and sharp legal thinker, but she’s a proven defender of the Constitution and conservative values.

    Taibleson spent over a decade as a federal prosecutor in the Eastern District of Wisconsin, putting violent criminals behind bars. She doesn’t just theorize about public safety–she delivers it. She handles complex appeals and knows how to write strong legal arguments, and she wins cases and protects communities. Every day in her career, she applies the law with clarity, discipline, and purpose.

    Most importantly, in her role as the co‑chief of the Appellate Division of that U.S. Attorney’s office for nearly a decade, not only did Taibleson imprison violent and dangerous criminals who were terrorizing the community, she ensured they stayed there. There are too many weak judges who free criminals when they should rot in prison for their crimes. Rebecca Taibleson is not one of them.

    Her credentials speak for themselves. She clerked for the late, great Justice Antonin Scalia and then-Judge Brett Kavanaugh. She embraced a constitutionalist philosophy early in her career and never wavered. At her Senate confirmation hearing, she made it crystal clear: judges must interpret the law as written, not how they wish it were written. Judges must not rewrite laws based on personal views or political trends. She follows the original public meaning of the law and honors the Constitution.

    Taibleson also knows how to stand her ground. During one of the most brutal nomination fights in recent memory, she stepped up and testified in support of her former boss Brett Kavanaugh, a nomination fight for which I helped lead the charge as Chairman Chuck Grassley’s chief counsel for nominations on the Senate Judiciary Committee. While the left smeared and attacked, Rebecca Taibleson didn’t flinch. She stood firm in defense of the rule of law and the truth. That moment proved her courage and character.

    She also served in President Trump’s solicitor general’s office — the top government appellate advocates. She fought and won legal battles at the Supreme Court. She defended Trump administration policies on immigration, religious liberty, and constitutional limits. She didn’t just serve under President Trump, she helped him win. Her record shows loyalty, competence, and backbone.

    Some groups have raised concerns—and even opposition before they had a chance to watch her testimony at her Senate confirmation hearing. Some are fair points; most are not. They wanted someone else. They’re circulating misleading claims and ignoring facts. They’re criticizing a nominee who far exceeds the standard for confirmation. President Trump and his team reviewed many good candidates. Like with any nominee, they balanced all the pros and cons. While no nominee is ever perfect, Rebecca Taibleson proved through her long record and unflinching public testimony that she is outstanding. She has a proven track record of being bold and fearless.

    Taibleson handled her confirmation hearing exactly the way a strong nominee should. She didn’t dodge questions or pander. She answered directly and confidently and laid out her commitment to textualism, originalism, and constitutionalism. She emphasized the separation of powers and reminded the Senate that judges don’t make policy. Elected officials do.

    On precedent, she spoke with clarity. She said Dobbs v. Jackson controls abortion law, and she will follow it. She refused to play politics with hot-button issues, but she left no doubt about her commitment to the Constitution.

    She also promised to bring civility and discipline to the bench. She won’t use opinions to take swipes at parties, public officials, or opposing views. She respects the role of the judiciary and knows the difference between law and politics. She pledged to uphold judicial restraint.

    Taibleson’s background shows real-world depth. Early in her career, she worked with Israel’s national emergency medical, disaster, ambulance, and blood bank service Magen David Adom during the Second Intifada. She helped defend civilians from terrorist attacks. That experience gave her a deeper understanding of law, national security, justice, and what is at stake for Western civilization. It also showed her values: courage, service, and loyalty to free societies under attack.

    Taibleson has answered the questions raised by her detractors from the left and the right. She addressed every issue and demonstrated exactly why she belongs on the Seventh Circuit. Her hearing and record proves her fitness. She showed strength, clarity, and deep legal knowledge. And she put to bed any concerns.

    President Trump built the best judicial legacy in a generation. He transformed the Supreme Court into the first constitutionalist Court in 90 years. He reshaped the federal judiciary with principled, constitutionalist judges. He made those choices carefully, and he made the same careful decision here. Rebecca Taibleson fits that mold. She brings real experience, proven loyalty, and a first-rate legal mind.

    The Senate must confirm this bold and fearless judicial nominee. She earned this seat by standing up when it counted. She served President Trump with distinction and fought for her country in the courts. She prosecuted criminals and protected communities. She embraces originalism and the rule of law.

    President Trump chose right. The Senate must finish the job.

    This post appeared first on FOX NEWS

    Senate Republicans rammed through dozens of President Donald Trump’s nominees on Thursday in their first flex of the Senate’s new rules for confirmations.

    Lawmakers voted along party lines to confirm 48 of Trump’s nominees, many being for undersecretary or assistant secretary positions in a variety of agencies throughout the federal government and ambassadorships.

    Senate Republicans went ‘nuclear’ last week to make the change after a last-minute deal with Democrats fell apart.

    The change ushered in by the ‘nuclear option’ allows lawmakers to confirm an unlimited number of nominees in batches, also known as en bloc, with a simple majority vote in the upper chamber. However, the process is time-consuming, given that lawmakers must jump through procedural hoops and allow for 30 hours of debate.

    ‘Why has not a single nominee been confirmed by voice vote or by unanimous consent? We know why,’ Senate Majority Whip John Barrasso, R-Wyo., said on the Senate floor. ‘It’s Democrat obstruction.

    ‘The country has never seen anything like this,’ he continued. ‘Senate Democrats are freezing the Senate floor, freezing the federal government and freezing our nation’s progress. This harms America’s safety. It hamstrings the agenda that Americans voted for.’

    Among this batch of nominees were Kimberly Guilfoyle, who Trump tapped to be the U.S. ambassador to Greece, and Callista Gingrich, who was picked to be the U.S. ambassador to Switzerland.

    Republicans argued that the change would benefit both parties now and in the future and viewed the change as an option of last resort to break through Senate Democrats’ blockade of Trump’s picks.

    Typically, subcabinet-level nominees, particularly those with bipartisan support out of committee, are sped through the Senate either by unanimous consent or through a voice vote, two fast-track procedural moves in the upper chamber. All the nominees in this first round made it out of committee on a bipartisan basis.

    However, Senate Minority Leader Chuck Schumer, D-N.Y., and his caucus wouldn’t allow either to be used and caused a backlog of nominees to lower level positions in the Trump administration to pile up. As of Thursday, the list had swollen to 173.

    The only one of Trump’s nominees that easily moved through the chamber was Secretary of State Marco Rubio, who was confirmed in January on a near unanimous vote. 

    This post appeared first on FOX NEWS

    Shortly after announcing a strategy to go after deceptive direct-to-consumer advertising by the pharmaceutical industry, Robert F. Kennedy Jr. and the Department of Health and Human Services released a parody video of a drug advertisement – a pointed way of emphasizing the fact that the United States is largely unique in allowing drug ads.

    ‘Tired of endless drug ads promising quick fixes but leaving you sicker than you were before? That can change today. Ask your doctor about MAHA,’ the parody commercial begins, referring to Kennedy’s ‘Make America Healthy Again’ initiative. 

    ‘MAHA may cause healthier living, fewer chronic diseases, and lower drug costs,’ the video’s narrator continues. ‘Some Americans reported more time spent with family instead of at the pharmacy. Other side effects may include healthier children, a stronger nation, more transparency in healthcare, honest advertising, and accountability from Big Pharma.’

    The drug advertisement parody comes after Kennedy and HHS laid out their plans to target direct-to-consumer drug advertising – something that isn’t widely allowed outside the United States – in a new children’s health strategy released earlier this month. 

    The strategy said it will ramp up enforcement of current prescription drug advertising laws, with a priority on ‘egregious violations demonstrating harm from current practices.’ The strategy noted these violations could include the dissemination of ‘risk information and quality of life through misleading and deceptive advertising on social media and digital platforms.’

    The strategy to go after direct-to-consumer drug ads will also include inter-agency cooperation to explore the development of potential new industry guidelines that limit direct-to-consumer advertising for certain ‘unhealthy foods’ to children. These efforts include ‘evaluating the use of misleading claims and imagery,’ the MAHA children’s strategy stated. 

    Kennedy said alongside the release of HHS’s parody advertisement that the Trump administration plans to begin holding the pharmaceutical industry accountable for not sharing full safety information in their drug ads on television, radio and beyond.

     

    ‘No more hiding vital information in small print, or pushing it off to a website, or a 1-800 number,’ Kennedy said in a video released in conjunction with the parody advertisement. He also noted that regulators have been letting pharmaceutical manufacturers avoid providing complete warnings in their marketing materials.

    Kennedy said in the accompanying video that, in the past, regulators let companies mention a vague ‘major statement’ of risk that required consumers to go elsewhere for important details about the drug. The secretary said this ‘loophole’ opened the door to a ‘tsunami’ of misleading advertisements.

    ‘Drug ads drove up prescription drug costs and distorted doctor-patient conversations. Patients saw glossy ads and often asked for new medications,’ Kennedy continued. ‘Big Pharma’s marketing hooked the country on prescription drugs. We’re taking action to end that practice.’

    This post appeared first on FOX NEWS